27748-08-9

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl 4-hydroxy-1H-indole-2-carboxylate is used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. Its hydroxyl and carboxylic acid groups enable the formation of esters, which are essential for the development of new drugs and other chemical products.
Used in Medicinal Applications:
Methyl 4-hydroxy-1H-indole-2-carboxylate is being studied for its potential medicinal applications, including its antioxidant and anti-inflammatory properties. Its unique structure and functional groups make it a promising candidate for the development of new therapeutic agents.
Used in Chemical Research:
Methyl 4-hydroxy-1H-indole-2-carboxylate is also used in chemical research to explore its properties and potential applications. Its structure and functional groups provide a foundation for understanding the behavior of similar compounds and their interactions with other molecules.

Upstream product

• 111258-23-2 methyl 4-methoxy-1H-indole-2-carboxylate 
• 90-02-8 salicylaldehyde 
• 117175-27-6 (Z)-2-Azido-3-(2-benzyloxy-phenyl)-acrylic acid methyl ester 
• 27748-09-0 4-benzyloxyindole-2-carboxylic acid methyl ester 

Downstream Products

• 1037763-09-9 C₂₄H₁₆F₂N₂O₄ 
• 1037757-57-5 6-(2,5-difluorobenzyl)-8-(2-oxo-1,2-dihydropyridin-3-yl)-6H-furo[2,3-e]indole-7-carboxylic acid 
• 1037758-50-1 C₂₄H₁₆F₂N₂O₄ 
• 1037758-03-4 C₂₅H₁₈F₂N₂O₄ 
• 1037759-30-0 C₂₄H₁₆F₂N₂O₄ 
• 796870-45-6 methyl 4-phenyl-1H-indole-2-carboxylate 
• 1037757-51-9 C₂₃H₁₅FN₂O₄ 
• 1037763-06-6 C₂₅H₁₉FN₂O₄ 
• 1037765-15-3 C₂₄H₁₇FN₂O₄ 
• 1037757-60-0 C₂₄H₁₈FN₃O₅S 

Relevant academic research and scientific papers

Discovery of novel tricyclic indole derived inhibitors of HCV NS5B RNA dependent RNA polymerase

The characterization of HCV genome has identified various vital functional proteins involved in the life cycle of hepatitis C virus. This has resulted in many novel enzymatic targets that are potential for development of therapeutic agents. The HCV RNA de

Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies

We report the design and synthesis of a series of dipeptide-type inhibitors with novel P3 scaffolds that display potent inhibitory activity against SARS-CoV 3CLpro. A docking study involving binding between the dipeptidic lead compound 4 and 3CLpro suggested the modification of a structurally flexible P3 N-(3-methoxyphenyl)glycine with various rigid P3 moieties in 4. The modifications led to the identification of several potent derivatives, including 5c-k and 5n with the inhibitory activities (Ki or IC50) in the submicromolar to nanomolar range. Compound 5h, in particular, displayed the most potent inhibitory activity, with a Ki value of 0.006 μM. This potency was 65-fold higher than the potency of the lead compound 4 (Ki = 0.39 μM). In addition, the Ki value of 5h was in very good agreement with the binding affinity (16 nM) observed in isothermal titration calorimetry (ITC). A SAR study around the P3 group in the lead 4 led to the identification of a rigid indole-2-carbonyl unit as one of the best P3 moieties (5c). Further optimization showed that a methoxy substitution at the 4-position on the indole unit was highly favorable for enhancing the inhibitory potency.

TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Tricyclic Indole Derivatives, compositions comprising at least one Tricyclic Indole Derivatives, and methods of using the Tricyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient

4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS

The present invention relates to 4,5-ring annulated indole derivatives, compositions comprising at least one 4,5-ring annulated indole derivatives, and methods of using the 4,5-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. Wherein ring Z, of formula (I), is a cyclopentyl, cyclopentenyl, 5-membered heterocycloalkyl, 5-membered heterocycloalkenyl or 5-membered heteroaryl ring.

CHEMOKINE RECEPTOR ANTAGONISTS

A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof, wherein the variants R, R9, Z, X, Q and Y are defined in the specification.

ANTI-INFLAMMATORY INDOLE DERIVATIVES

Compounds of formula (I) or a pharmaceutically acceptable salt, in vivo hydrolysable ester, or an N-C1-6alkyl or N,N-di-(C1-6alkyl)amide thereof, where X is CH2 or SO2; R1 is an aryl optionally substituted by alkyl, alkenyl, alkynyl, halo, haloalkyl inclu

Monocyte chemoattractant protein-1 inhibitor compounds

The invention concerns the use of a compound of the formula (I) in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.

Indole derivatives as MCP-1 receptor antagonists

The invention concerns pharmaceutically useful indoles of formula (I), in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, as well